These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 18553563)

  • 21. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
    Mosse YP; Greshock J; Margolin A; Naylor T; Cole K; Khazi D; Hii G; Winter C; Shahzad S; Asziz MU; Biegel JA; Weber BL; Maris JM
    Genes Chromosomes Cancer; 2005 Aug; 43(4):390-403. PubMed ID: 15892104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coamplification of multiple regions of chromosome 2, including MYCN, in a single patchwork amplicon in cancer cell lines.
    Kitada K; Aida S; Aikawa S
    Cytogenet Genome Res; 2012; 136(1):30-7. PubMed ID: 22123490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
    Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
    BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors.
    Schaub R; Burger A; Bausch D; Niggli FK; Schäfer BW; Betts DR
    Cancer Genet Cytogenet; 2007 Jan; 172(1):61-5. PubMed ID: 17175381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
    Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
    Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
    Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
    J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.
    Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T
    Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
    Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
    Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
    Alaminos M; Gerald WL; Cheung NK
    Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
    Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
    Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
    Mosse YP; Diskin SJ; Wasserman N; Rinaldi K; Attiyeh EF; Cole K; Jagannathan J; Bhambhani K; Winter C; Maris JM
    Genes Chromosomes Cancer; 2007 Oct; 46(10):936-49. PubMed ID: 17647283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays.
    Carr J; Bown NP; Case MC; Hall AG; Lunec J; Tweddle DA
    Cancer Genet Cytogenet; 2007 Jan; 172(2):127-38. PubMed ID: 17213021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization.
    Wan TS; Ma ES; Chan GC; Chan LC
    Int J Mol Med; 2004 Dec; 14(6):981-7. PubMed ID: 15547663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
    Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
    Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
    Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
    Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk estimation of neuroblastoma patients using molecular markers.
    Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
    Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma.
    Fulda S; Poremba C; Berwanger B; Häcker S; Eilers M; Christiansen H; Hero B; Debatin KM
    Cancer Res; 2006 Oct; 66(20):10016-23. PubMed ID: 17047064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma.
    Combaret V; Bergeron C; Noguera R; Iacono I; Puisieux A
    J Clin Oncol; 2005 Dec; 23(34):8919-20; author reply 8920. PubMed ID: 16314658
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.